WATCH: Nearly 70 percent of early breast cancer patients may not need chemotherapy: Study

The trial used a gene test done on tumors to help decide whether a woman would benefit from chemo or if they could receive hormone therapy.
Source: ABC News: Health - Category: Consumer Health News Tags: WNT Source Type: news

Related Links:

A 59-year-old woman with a history of right-sided breast cancer presents with new onset of a right lower neck mass and numbness/paresthesia over her anterior/medial deltoid.1 Three years earlier, she received a diagnosis of stage IIIA disease (cT3N1), ER/PR+ and Her-2 nonreactive. She received neoadjuvant chemotherapy followed by modified radical mastectomy and adjuvant chemotherapy. However, she did not receive postmastectomy radiation or proper hormone therapy because of their cost.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Authors: Allahverdiyev A, Tari G, Bagirova M, Abamor ES Abstract Cancer is the leading cause of death worldwide. In developed as well as developing countries, breast cancer is the most common cancer found among women. Currently, treatment of breast cancer consists mainly of surgery, chemotherapy, hormone therapy, and radiotherapy. In recent years, because of increased understanding of the therapeutic potential of immunotherapy in cancer prevention, cancer vaccines have gained importance. Here, we review various immunotherapeutic breast cancer vaccines including peptide-based vaccines, whole tumor cell vaccines, gen...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
. Efird In this US-based study of the National Cancer Database (NCDB), we examined 8550 patients diagnosed with non-metastatic, invasive inflammatory breast cancer (IBC) who received surgery from 2004–2013. Patients were grouped into four biologic subtypes (HR+/HER2−, HR+/HER2+, HR−/HER2+, HR−/HER2−). On average, women were 56 years of age at diagnosis and were followed for a median of 3.7 years. The majority were white (80%), had private health insurance (50%), and presented with poorly differentiated tumors (57%). Approximately 46% of the cancers were >5 cm. Most patients underwen...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice. Breast. 2019 Jan 03;44:39-45 Authors: Curtit E, Vannetzel JM, Darmon JC, Roche S, Bourgeois H, Dewas S, Catala S, Mereb E, Fanget CF, Genet D, Forest AM, Bernier C, Pivot X Abstract Adjuvant chemotherapy shows clear benefits in HER2-positive and triple-negative breast cancer (BC). Its benefits are less universal in BCs expressing hormone receptors. The 21-gene Oncotype DX® Breast Recurrence Score test was designed for HR+, HER2- early...
Source: Breast - Category: Cancer & Oncology Authors: Tags: Breast Source Type: research
ConclusionsThe local recurrence risk reduction of the tumour bed boost in breast-conserving therapy is not influenced by the applied boost technique.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
Authors: Mohamad Hanif EA, Shah SA Abstract Breast cancer treatments leads to variable responses. Hormonal therapy is beneficial to receptor positive breast cancer subtypes and display better clinical outcome than triple negative breast cancers (TNBCs) with FEC (5-Fluorouracil, Epirubicin and Cyclophosphamide) the mainstay chemotherapy regiment. Owning to their negative expressions of estrogen (ER), progesterone (PR) and HER2 receptors, disease recurrence and metastasis befalls some patients indicating resistance to FEC. Involvement of epigenetic silencing through DNA methylation, histone methylation, acetylation a...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
CONCLUSION: Although hypofractionation theoretically exposes the thyroid gland to late radiotherapy complications, radiation-induced dysthyroidism remains a complication underestimated by clinicians, and in the absence of prevention and treatment guidelines, it is necessary to delineate systematically the thyroid gland, to try to minimize as much as possible the doses received by this organ, and to monitor the thyroid function by periodic serum assays. PMID: 30595341 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
(American Association for Cancer Research) Circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer, according to data from the phase III STIC CTC clinical trial presented at the 2018 San Antonio Breast Cancer Symposium. In the case of discrepancy between CTC count-based treatment choice and physician's choice of treatment, frontline chemotherapy was associated with a significant gain in overall survival.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
We present a rare case of breast cancer in female-to-male transsexual patient after long-term hormonal therapy. Diagnosis: Breast cancer in female-to-male transsexual patient. Interventions: The patient underwent mastectomy and chemotherapy. Outcomes: The patient had local recurrence of the disease and he underwent re-excision, radiotherapy and the tamoxifen treatment. After this treatment, the patient is in the remission from the disease. Lessons: Breast cancer in transsexuals appears to be rare. However, there is a potential risk that testosterone exposure can increase the risk of developing breast cancer by ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Conclusion: Unlike the natural behavior of BD, which is well-defined to have an increased risk of thrombosis, BC patients with BD in this study did not have any adverse event. However, due to small sample size, it is difficult to drive any definite conclusion regarding the relation between these two pathologies.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Health | Hormonal Therapy | Hormones | Study